Improvement bioavailability of silymarin ameliorates severe dyslipidemia associated with metabolic syndrome

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F15%3A33155422" target="_blank" >RIV/61989592:15110/15:33155422 - isvavai.cz</a>

Alternative codes found

RIV/00023001:_____/15:00059567

Result on the web

<a href="http://dx.doi.org/10.3109/00498254.2015.1010633" target="_blank" >http://dx.doi.org/10.3109/00498254.2015.1010633</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3109/00498254.2015.1010633" target="_blank" >10.3109/00498254.2015.1010633</a>

Result language

angličtina

Original language name

Improvement bioavailability of silymarin ameliorates severe dyslipidemia associated with metabolic syndrome

Original language description

1. To compare the effectiveness of different drug forms of silymarin: standardized extract of silymarin (SS), micronized silymarin (MS) and silymarin in the form of phytosome (PS) on dyslipidemia and liver fat accumulation in a model of metabolic syndrome, in non-obese hereditary hypertriglyceridemic rats. The second aim of this study was to slightly uncover the silymarin action on enzymes and proteins involved in cholesterol metabolism and excretion. 2. Silymarin administered to hereditary hypertriglyceridemic rats as dietary supplements (1%) for 4 weeks significantly lowered the plasma levels of triglycerides, total cholesterol and markedly increased HDL cholesterol level. Western blot analyses showed significant increase in the protein expression ofCYP7A1 and CYP4A and increase in protein expression of selected ABC transporters. Silymarin in the form of phytosome and micronized silymarin were more effective forms of silymarin. 3. These findings suggest that silymarin may favorably

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FR - Pharmacology and apothecary chemistry

OECD FORD branch

—

Project

<a href="/en/project/GA13-10813S" target="_blank" >GA13-10813S: Natural polyphenolic substances in experimental pharmacology of metabolic syndrome</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2015

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Xenobiotica

ISSN

0049-8254

e-ISSN

—

Volume of the periodical

45

Issue of the periodical within the volume

9

Country of publishing house

GB - UNITED KINGDOM

Number of pages

6

Pages from-to

751-756

UT code for WoS article

000361325400001

EID of the result in the Scopus database

—